Inhibrx Biosciences earnings were -$130.2M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest INBX earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$33.4M, up 1.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, INBX reported annual earnings of -$140.1M, with -108.3% growth.
Inhibrx Biosciences Earnings Reports & History FAQ
What were Inhibrx Biosciences's earnings last quarter?
Inhibrx Biosciences (NASDAQ: INBX) reported Q1 2026 earnings per share (EPS) of -$2.15, up 23.21% year over year. Total INBX earnings for the quarter were -$33.44 million. In the same quarter last year, Inhibrx Biosciences's earnings per share (EPS) was -$2.80.
Is Inhibrx Biosciences profitable or losing money?
As of the last Inhibrx Biosciences earnings report, Inhibrx Biosciences is currently losing money. Inhibrx Biosciences's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$130.19 million, a 107.56% decrease year over year.
What was INBX's earnings growth in the past year?
As of Inhibrx Biosciences's earnings date in Q2 2026, Inhibrx Biosciences's earnings has grown year over year. INBX earnings in the past year totalled -$130.19 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.